StephanieMehlisMD

Dermatology • Skokie, IL

Director, Dermatology Clinical Trials Unit

Join to view full profile

Dr. Mehlis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mehlis' full profile

Already have an account?

Office
9933 Woods Dr
# 2
Skokie, IL 60077
Phone+1 847-663-8060

Fax+1 847-733-5315

Education & Training

McGaw Medical Center of Northwestern UniversityResidency, Dermatology, 2003 - 2006
Northwestern University The Feinberg School of MedicineClass of 2001

Certifications & Licensure

IL State Medical License 2001 - 2026
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Psoriasis Longitudinal Assessment and Registry Start of enrollment: 2007 Jun 21
Active, not recruiting
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) Start of enrollment: 2012 Jul 28
Completed
Phase 3
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Start of enrollment: 2014 Oct 07
Completed
Phase 3
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Start of enrollment: 2014 Nov 03
Completed
Phase 3
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment Start of enrollment: 2016 Feb 29
Completed
Phase 3
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) Start of enrollment: 2022 May 06
Withdrawn
Phase 3
Roles: Contact, Principal Investigator
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period Start of enrollment: 2023 Nov 06
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

97 citations
Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
Alice B. Gottlieb, C. Leonardi, Francisco A. Kerdel, Stephanie L Mehlis, M. Olds
The British Journal of Dermatology. 2011-09-01
63 citations
The immunology of psoriasis and biologic immunotherapy
Stephanie L Mehlis, Kenneth B. Gordon
Journal of the American Academy of Dermatology. 2003-08-01
31 citations
Treating psoriasis with adalimumab.
Eihab Alwawi, Stephanie L Mehlis, Kenneth B. Gordon
Therapeutics and Clinical Risk Management. 2008-04-01

Journal Articles

Biologics for the Primary Care Physician: Review and Treatment of Psoriasis
Stephanie L Mehlis, Eric D Schadler, Bernhard Ortel, ScienceDirect

Other

Guttate psoriasis
Mehlis S
http://www.uptodate.com/contents/guttate-psoriasis
UpToDate, Wolters Kluwer Health - 2012-07-24

Press Mentions

Know Your Skin: Psoriasis Symptoms & Treatment OptionsFebruary 22nd, 2016